{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:24:39Z","timestamp":1783488279862,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"HRA Pharma","award":["8000.21"],"award-info":[{"award-number":["8000.21"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40262-020-00913-y","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:05:07Z","timestamp":1593543907000},"page":"89-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-6040","authenticated-orcid":false,"given":"Anyue","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2577-4187","authenticated-orcid":false,"given":"Madeleine H. T.","family":"Ettaieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"van Deun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M. A.","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J. H. M.","family":"van der Straaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora P. M.","family":"Corssmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel N.","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marelise","family":"Eekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri J. L. M.","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"issue":"2","key":"913_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17925\/EE.2018.14.2.62","volume":"14","author":"RM Paragliola","year":"2018","unstructured":"Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma\u2014review and state of the art. Eur Endocrinol. 2018;14(2):62\u20136. https:\/\/doi.org\/10.17925\/EE.2018.14.2.62.","journal-title":"Eur Endocrinol."},{"issue":"1","key":"913_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/bf00258213","volume":"7","author":"AJ Moolenaar","year":"1981","unstructured":"Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D. Blood levels of o, p\u2019-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol. 1981;7(1):51\u20134. https:\/\/doi.org\/10.1007\/bf00258213.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"913_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/EJE-18-0342","volume":"179","author":"U Arshad","year":"2018","unstructured":"Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, et al. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. Eur J Endocrinol. 2018;179(5):287\u201397. https:\/\/doi.org\/10.1530\/EJE-18-0342.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"913_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/bf00265384","volume":"9","author":"H Vanslooten","year":"1982","unstructured":"Vanslooten H, Vanseters AP, Smeenk D, Moolenaar AJ. O, P\u2019-Ddd (Mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemoth Pharm. 1982;9(2):85\u20138. https:\/\/doi.org\/10.1007\/bf00265384.","journal-title":"Cancer Chemoth Pharm."},{"issue":"12","key":"913_CR5","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1210\/jc.2013-2281","volume":"98","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4759\u201367. https:\/\/doi.org\/10.1210\/jc.2013-2281.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"913_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1634\/theoncologist.2015-0322","volume":"21","author":"N Buil-Bruna","year":"2016","unstructured":"Buil-Bruna N, Lopez-Picazo JM, Martin-Algarra S, Troconiz IF. Bringing model-based prediction to oncology clinical practice: a review of pharmacometrics principles and applications. Oncologist. 2016;21(2):220\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2015-0322.","journal-title":"Oncologist."},{"issue":"11","key":"913_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/pharmaceutics11110566","volume":"11","author":"Y Cazaubon","year":"2019","unstructured":"Cazaubon Y, Talineau Y, Feliu C, Konecki C, Russello J, Mathieu O, et al. Population pharmacokinetics modelling and simulation of mitotane in patients with adrenocortical carcinoma: an individualized dose regimen to target all patients at three months? Pharmaceutics. 2019;11(11):566. https:\/\/doi.org\/10.3390\/pharmaceutics11110566.","journal-title":"Pharmaceutics."},{"issue":"1","key":"913_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/FTD.0000000000000102","volume":"37","author":"TM Kerkhofs","year":"2015","unstructured":"Kerkhofs TM, Derijks LJ, Ettaieb H, den Hartigh J, Neef K, Gelderblom H, et al. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. Ther Drug Monit. 2015;37(1):58\u201365. https:\/\/doi.org\/10.1097\/FTD.0000000000000102.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"913_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S1470-2045(05)70388-0","volume":"6","author":"CD Scripture","year":"2005","unstructured":"Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6(10):780\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(05)70388-0.","journal-title":"Lancet Oncol."},{"issue":"6","key":"913_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/FPC.0b013e3283606cb2","volume":"23","author":"A D\u2019Avolio","year":"2013","unstructured":"D\u2019Avolio A, De Francia S, Basile V, Cusato J, De Martino F, Pirro E, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013;23(6):293\u2013300. https:\/\/doi.org\/10.1097\/FPC.0b013e3283606cb2.","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"913_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/bmc.2696","volume":"26","author":"A Mornar","year":"2012","unstructured":"Mornar A, Sertic M, Turk N, Nigovic B, Korsic M. Simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by SPE-HPLC technique. Biomed Chromatogr. 2012;26(11):1308\u201314. https:\/\/doi.org\/10.1002\/bmc.2696.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"913_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2265.2010.03787.x","volume":"73","author":"IG Hermsen","year":"2010","unstructured":"Hermsen IG, den Hartigh J, Haak HR. Mitotane serum level analysis; good agreement between two different assays. Clin Endocrinol (Oxf). 2010;73(2):271\u20132. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03787.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"913_CR13","doi-asserted-by":"publisher","first-page":"F632","DOI":"10.1152\/ajprenal.1984.247.4.F632","volume":"247","author":"P Boer","year":"1984","unstructured":"Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol Endocrinol Metabol. 1984;247(4):F632\u20136. https:\/\/doi.org\/10.1152\/ajprenal.1984.247.4.F632.","journal-title":"Am J Physiol Endocrinol Metabol."},{"issue":"33","key":"913_CR14","doi-asserted-by":"publisher","first-page":"54028","DOI":"10.18632\/oncotarget.9927","volume":"7","author":"M Arbitrio","year":"2016","unstructured":"Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, et al. DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. Oncotarget. 2016;7(33):54028\u201350. https:\/\/doi.org\/10.18632\/oncotarget.9927.","journal-title":"Oncotarget."},{"issue":"8","key":"913_CR15","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106\u201312. https:\/\/doi.org\/10.1182\/blood-2007-11-122010.","journal-title":"Blood"},{"issue":"3","key":"913_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/14622416.8.3.293","volume":"8","author":"C Dumaual","year":"2007","unstructured":"Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics. 2007;8(3):293\u2013305. https:\/\/doi.org\/10.2217\/14622416.8.3.293.","journal-title":"Pharmacogenomics."},{"key":"913_CR17","unstructured":"Affymetrix\u00ae. White Paper: DMET\u2122 Plus allele translation reports: summary of comprehensive drug disposition genotyping into commonly recognized allele names 2012. http:\/\/tools.thermofisher.com\/content\/sfs\/brochures\/dmet_plus_translation.pdf. Accessed 6 Jan 2020."},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-60761-663-4_7","volume":"632","author":"JK Burmester","year":"2010","unstructured":"Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol. 2010;632:99\u2013124. https:\/\/doi.org\/10.1007\/978-1-60761-663-4_7.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"913_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2217\/pgs.09.154","volume":"11","author":"TM Sissung","year":"2010","unstructured":"Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics. 2010;11(1):89\u2013103. https:\/\/doi.org\/10.2217\/pgs.09.154.","journal-title":"Pharmacogenomics."},{"key":"913_CR20","unstructured":"Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther. 2009;11(3):260\u20138. PMID 19479659."},{"issue":"2","key":"913_CR21","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131. https:\/\/doi.org\/10.1002\/prp2.131.","journal-title":"Pharmacol Res Perspect."},{"key":"913_CR22","doi-asserted-by":"publisher","unstructured":"Hecht M, Veigure R, Couchman L, CI SB, Standing JF, Takkis K et al. Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis. 2018;10(15):1229\u201348. https:\/\/doi.org\/10.4155\/bio-2018-0078.","DOI":"10.4155\/bio-2018-0078"},{"issue":"9","key":"913_CR23","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687.","journal-title":"Pharm Res"},{"issue":"2","key":"913_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"1","key":"913_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/psp4.12052","volume":"5","author":"W Wang","year":"2016","unstructured":"Wang W, Hallow KM, James DA. A tutorial on RxODE: simulating differential equation pharmacometric models in R. CPT Pharmacometr Syst Pharmacol. 2016;5(1):3\u201310. https:\/\/doi.org\/10.1002\/psp4.12052.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"key":"913_CR26","unstructured":"Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Mitotaan. 2019. https:\/\/kennisbank.knmp.nl\/article\/Informatorium_Medicamentorum\/S1853.html. Accessed 28 Aug 2019."},{"issue":"4","key":"913_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","volume":"92","author":"M Whirl-Carrillo","year":"2012","unstructured":"Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414\u20137. https:\/\/doi.org\/10.1038\/clpt.2012.96.","journal-title":"Clin Pharmacol Ther"},{"key":"913_CR28","unstructured":"PharmGKB. rs4244285, Variant annotation. https:\/\/www.pharmgkb.org\/variant\/PA166154053\/variantAnnotation. Accessed 28 Aug 2019."},{"key":"913_CR29","unstructured":"PharmGKB. rs7311358, Clinical annotation. https:\/\/www.pharmgkb.org\/variant\/PA166154602\/clinicalAnnotation. Accessed 28 Aug 2019."},{"key":"913_CR30","unstructured":"PharmGKB. rs4149117, Clinical annotation. https:\/\/www.pharmgkb.org\/variant\/PA166154583\/clinicalAnnotation. Accessed 28 Aug 2019."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00913-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T23:44:43Z","timestamp":1625010283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00913-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00913-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"30 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was partially supported by HRA Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anyue Yin, Madeleine H.T. Ettaieb, Jesse J. Swen, Liselotte van Deun, Thomas M.A. Kerkhofs, Robert J.H.M van der Straaten, Eleonora P.M. Corssmit, Hans Gelderblom, Michiel N. Kerstens, Richard A. Feelders, Marelise Eekhoff, Henri J.L.M. Timmers, Antonio D\u2019Avolio, Jessica Cusato, Henk-Jan Guchelaar, Harm R. Haak, and Dirk Jan A.R. Moes declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Medical Ethical Committee of the M\u00e1xima Medical Center Veldhoven (2015), and approval for the inclusion of patients in other institutes was obtained from the local boards. All procedures performed in this study were in accordance with the ethical standards of the institutional Medical Ethical Committee and the 1964 Helsinki Declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The required informed consents were obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"PopPK analysis was performed using the FOCEI method implemented in NONMEM software version 7.4.1 (ICONDevelopment Solutions). Statistical analysis, plot generation, and simulations were performed using R version 3.6.1 (The R Foundation for Statistical Computing). The R script of the Shiny application established in this study for simulation can be found at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}